Project acronym AbioEvo
Project Conditions for the emergence of evolution during abiogenesis
Researcher (PI) Philippe Nghe
Host Institution (HI) ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS
Country France
Call Details Consolidator Grant (CoG), LS1, ERC-2020-COG
Summary Abiogenesis, the transition from non-living to living matter, is at the core of the origin of life question. However, the dynamical processes underlying abiogenesis remain unknown.
The AbioEvo project aims to test the hypothesis that RNA-catalysed RNA recombination, if coupled with template-based mechanisms, provides a gradual route for the emergence of evolution by natural selection, starting from collective autocatalysis, toward template-based replication. Indeed, recombination allows both self-reproduction and shuffling of other sequences, thus, once combined with templating, provides the basic ingredients of reproduction, heredity and variation required for Darwinian evolution.
The project decomposes the problem into five steps: (WP1) the study of molecular-level mechanisms to generate and stabilize novel sequences by recombination and templating; (WP2) collective dynamics integrating these mechanisms into the properties of reproduction with heredity, variation, and selection, in order to establish proof-of-concepts of evolutionary modes; (WP3) viability thresholds of recombination-based replicators from increasingly random substrates; (WP4) conditions for open-ended evolution toward template-based replication; (WP5) experimentally informed theoretical estimates of the probability of the proposed evolutionary transitions.
The project would provide first demonstrations of evolution by natural selection in a purely chemical system, gradual and experimentally accessible paths from oligomers to template-based replication, and a method to evaluate prebiotic plausibility from sequence-to-function relationships, kinetics and evolutionary dynamics.
Summary
Abiogenesis, the transition from non-living to living matter, is at the core of the origin of life question. However, the dynamical processes underlying abiogenesis remain unknown.
The AbioEvo project aims to test the hypothesis that RNA-catalysed RNA recombination, if coupled with template-based mechanisms, provides a gradual route for the emergence of evolution by natural selection, starting from collective autocatalysis, toward template-based replication. Indeed, recombination allows both self-reproduction and shuffling of other sequences, thus, once combined with templating, provides the basic ingredients of reproduction, heredity and variation required for Darwinian evolution.
The project decomposes the problem into five steps: (WP1) the study of molecular-level mechanisms to generate and stabilize novel sequences by recombination and templating; (WP2) collective dynamics integrating these mechanisms into the properties of reproduction with heredity, variation, and selection, in order to establish proof-of-concepts of evolutionary modes; (WP3) viability thresholds of recombination-based replicators from increasingly random substrates; (WP4) conditions for open-ended evolution toward template-based replication; (WP5) experimentally informed theoretical estimates of the probability of the proposed evolutionary transitions.
The project would provide first demonstrations of evolution by natural selection in a purely chemical system, gradual and experimentally accessible paths from oligomers to template-based replication, and a method to evaluate prebiotic plausibility from sequence-to-function relationships, kinetics and evolutionary dynamics.
Max ERC Funding
2 000 000 €
Duration
Start date: 2021-06-01, End date: 2026-05-31
Project acronym ACCENT
Project How antibodies and complement orchestrate protective immune responses against bacteria
Researcher (PI) suzan ROOIJAKKERS
Host Institution (HI) UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Country Netherlands
Call Details Consolidator Grant (CoG), LS6, ERC-2020-COG
Summary Due to antibiotic resistance, there is now great interest in the development of antibody-based therapies against bacterial infections, for instance via antibodies that boost the host immune system. In order to kill bacteria, antibodies should trigger activation of the complement cascade, which forms bactericidal Membrane Attack Complex (MAC) pores and strongly enhances phagocytosis. Although the power of complement could be exploited for antibody therapies, such developments are hampered by our limited insights into the mechanisms underlying antibody-dependent complement activation on bacteria. My team has developed unique assays to study complement activation on bacteria. In this proposal, we will combine our function-driven approaches with novel B cell sequencing methods to identify anti-bacterial antibodies with strong complement-activating potential. We will develop novel approaches to identify the variable (VH:VL) sequences of human antibodies that recognize whole bacterial cells. After FACS sorting of memory B cells or yeast Fab display, we will use multi-well functional assays to select monoclonal antibodies driving potent complement activation and subsequent killing of E. coli (via neutrophils or MAC). Thanks to our unique tools and unprecedented insights, we are in an unique position to decipher basic mechanisms by which antibodies induce bacterial killing via neutrophils or MAC. We will combine live-cell imaging and structural approaches to determine how bactericidal antibodies assemble lethal MAC pores in the bacterial cell envelope. Finally, we will explore the design of potent antibody combinations and study the mechanisms by which antibodies steer different effector functions, both in the context of clinical and non-pathogenic E. coli strains. Altogether, this grant will lead to fundamental knowledge about the functioning of the immune system and provide a biological basis for the development of antibody-based therapies against bacteria.
Summary
Due to antibiotic resistance, there is now great interest in the development of antibody-based therapies against bacterial infections, for instance via antibodies that boost the host immune system. In order to kill bacteria, antibodies should trigger activation of the complement cascade, which forms bactericidal Membrane Attack Complex (MAC) pores and strongly enhances phagocytosis. Although the power of complement could be exploited for antibody therapies, such developments are hampered by our limited insights into the mechanisms underlying antibody-dependent complement activation on bacteria. My team has developed unique assays to study complement activation on bacteria. In this proposal, we will combine our function-driven approaches with novel B cell sequencing methods to identify anti-bacterial antibodies with strong complement-activating potential. We will develop novel approaches to identify the variable (VH:VL) sequences of human antibodies that recognize whole bacterial cells. After FACS sorting of memory B cells or yeast Fab display, we will use multi-well functional assays to select monoclonal antibodies driving potent complement activation and subsequent killing of E. coli (via neutrophils or MAC). Thanks to our unique tools and unprecedented insights, we are in an unique position to decipher basic mechanisms by which antibodies induce bacterial killing via neutrophils or MAC. We will combine live-cell imaging and structural approaches to determine how bactericidal antibodies assemble lethal MAC pores in the bacterial cell envelope. Finally, we will explore the design of potent antibody combinations and study the mechanisms by which antibodies steer different effector functions, both in the context of clinical and non-pathogenic E. coli strains. Altogether, this grant will lead to fundamental knowledge about the functioning of the immune system and provide a biological basis for the development of antibody-based therapies against bacteria.
Max ERC Funding
2 000 000 €
Duration
Start date: 2021-06-01, End date: 2026-05-31
Project acronym AI-PREVENT
Project A nationwide artificial intelligence risk assessment for primary prevention of cardiometabolic diseases
Researcher (PI) Andrea Ganna
Host Institution (HI) HELSINGIN YLIOPISTO
Country Finland
Call Details Starting Grant (StG), LS7, ERC-2020-STG
Summary Diabetes, stroke and coronary artery disease (cardiometabolic diseases) are the leading cause of death in Europe. Given that effective pharmacological and lifestyle interventions are available, it is important to identify high risk individuals at an early stage. Traditionally, this is done using clinical prediction models. However, the established models have substantial limitations: they are often used by doctors only when an underlying disease is already suspected, they are not developed on updated nationally-representative data and they require time-consuming clinical measurements. Thus, a substantial part of the population is not provided with risk assessment. I propose to revolutionize the existing approaches to primary prevention by providing risk assessment of cardiometabolic diseases before an individual even steps into the doctor’s office for a visit. To this end my project has three main objectives:
1) Development of artificial intelligence (AI) approaches to model health trajectories based on nationwide registry data on medications, diagnoses, familial risk and socio-demographic information to obtain accurate risk estimates for cardiometabolic disease. I will integrate high quality data from selected countries that have long traditions of registry data (Finland and Sweden, over 7.5 million individuals).
2) To identify health trajectories that maximize the clinical utility of genetic scores by integrating genetic and registry-based data on > 1 million people to identify subgroups of individuals for whom genetic information might improve risk prediction.
3) Validation of AI and genetic-based risk assessment as first-stage screening via a clinical study in 2800 individuals.
My project leverages the latest developments in AI and high-quality data of unprecedented scale to deliver a paradigm shift with important public health consequences by potentially changing the way cardiometabolic disease risk is assessed.
Summary
Diabetes, stroke and coronary artery disease (cardiometabolic diseases) are the leading cause of death in Europe. Given that effective pharmacological and lifestyle interventions are available, it is important to identify high risk individuals at an early stage. Traditionally, this is done using clinical prediction models. However, the established models have substantial limitations: they are often used by doctors only when an underlying disease is already suspected, they are not developed on updated nationally-representative data and they require time-consuming clinical measurements. Thus, a substantial part of the population is not provided with risk assessment. I propose to revolutionize the existing approaches to primary prevention by providing risk assessment of cardiometabolic diseases before an individual even steps into the doctor’s office for a visit. To this end my project has three main objectives:
1) Development of artificial intelligence (AI) approaches to model health trajectories based on nationwide registry data on medications, diagnoses, familial risk and socio-demographic information to obtain accurate risk estimates for cardiometabolic disease. I will integrate high quality data from selected countries that have long traditions of registry data (Finland and Sweden, over 7.5 million individuals).
2) To identify health trajectories that maximize the clinical utility of genetic scores by integrating genetic and registry-based data on > 1 million people to identify subgroups of individuals for whom genetic information might improve risk prediction.
3) Validation of AI and genetic-based risk assessment as first-stage screening via a clinical study in 2800 individuals.
My project leverages the latest developments in AI and high-quality data of unprecedented scale to deliver a paradigm shift with important public health consequences by potentially changing the way cardiometabolic disease risk is assessed.
Max ERC Funding
1 550 057 €
Duration
Start date: 2021-01-01, End date: 2025-12-31
Project acronym AIM.imaging.CKD
Project AI-augmented, Multiscale Image-based Diagnostics of Chronic Kidney Disease
Researcher (PI) Peter BOOR
Host Institution (HI) UNIVERSITAETSKLINIKUM AACHEN
Country Germany
Call Details Consolidator Grant (CoG), LS7, ERC-2020-COG
Summary Chronic kidney disease (CKD) is a major global health problem, affecting 10% of the world population and projected to be the fifth major cause of death in 2040. CKD patients are one of the most complex and multi-morbid populations in internal medicine while at the same time having the least translational randomized clinical trials and limited treatment options. One of the major reasons for this is the lack of reproducible approaches specifically reflecting intrarenal pathological processes and disease activity. The overall goal of AIM.imaging.CKD is to specifically address this unmet need by developing, validating and integrating image-based diagnostics for CKD. The integration of broad interdisciplinary expertise will enable to develop a multiscale approach from nano- to micro- to macromorphological and molecular diagnostics. Specifically, the project will develop augmented full-spectrum ultrastructural (“nano”) and histological (“micro”) renal biopsy diagnostics, focusing on reproducible, quantitative nephropathological analyses and prediction of clinically relevant outcome parameters. The project will also explore macro-morphological and molecular imaging in CKD, focusing on translatable non-invasive approaches. The central feature will be the development of advanced, scalable and modular image analyses models utilizing artificial intelligence (AI), particularly machine and deep learning. Using preclinical testing and clinical validation, the main emphasis will be on accelerated or, whenever possible, direct implementation into the clinical practice. The integration of the above-mentioned tools and technologies provides a comprehensive multiscale and multiplex approach for improved diagnostics of CKD patients and facilitate future randomized clinical trials. At each level, and even more so when integrated, the results are expected to augment and transform image-based diagnostics of kidney diseases, and thereby lead to improved patient management and outcome.
Summary
Chronic kidney disease (CKD) is a major global health problem, affecting 10% of the world population and projected to be the fifth major cause of death in 2040. CKD patients are one of the most complex and multi-morbid populations in internal medicine while at the same time having the least translational randomized clinical trials and limited treatment options. One of the major reasons for this is the lack of reproducible approaches specifically reflecting intrarenal pathological processes and disease activity. The overall goal of AIM.imaging.CKD is to specifically address this unmet need by developing, validating and integrating image-based diagnostics for CKD. The integration of broad interdisciplinary expertise will enable to develop a multiscale approach from nano- to micro- to macromorphological and molecular diagnostics. Specifically, the project will develop augmented full-spectrum ultrastructural (“nano”) and histological (“micro”) renal biopsy diagnostics, focusing on reproducible, quantitative nephropathological analyses and prediction of clinically relevant outcome parameters. The project will also explore macro-morphological and molecular imaging in CKD, focusing on translatable non-invasive approaches. The central feature will be the development of advanced, scalable and modular image analyses models utilizing artificial intelligence (AI), particularly machine and deep learning. Using preclinical testing and clinical validation, the main emphasis will be on accelerated or, whenever possible, direct implementation into the clinical practice. The integration of the above-mentioned tools and technologies provides a comprehensive multiscale and multiplex approach for improved diagnostics of CKD patients and facilitate future randomized clinical trials. At each level, and even more so when integrated, the results are expected to augment and transform image-based diagnostics of kidney diseases, and thereby lead to improved patient management and outcome.
Max ERC Funding
1 999 375 €
Duration
Start date: 2021-05-01, End date: 2026-04-30
Project acronym ALIENIMPACTS
Project Predicting impacts of alien plant invasions on community diversity
Researcher (PI) Jane Catford
Host Institution (HI) KING'S COLLEGE LONDON
Country United Kingdom
Call Details Consolidator Grant (CoG), LS8, ERC-2020-COG
Summary The Anthropocene, the current geological epoch, is characterised by human-induced ecological changes, which have prompted a global biodiversity crisis. Human-introduced alien plants could help to offset native species loss, augmenting diversity and maintaining the services and capital that humans derive from nature. However, alien species that become invasive are themselves a key threat to biodiversity. Alien species thus presents a huge challenge for biodiversity conservation in the Anthropocene: should their arrival and establishment be inhibited or disregarded as they can potentially both exacerbate and ameliorate biodiversity loss? Coupling empirical and theoretical approaches, ALIENIMPACTS will directly address this challenge by developing an approach for accurately predicting impacts of alien plant invasions on plant community diversity and identifying the circumstances under which negative impacts will occur. Using temperate grasslands as a model system, ALIENIMPACTS will use innovative field experiments and global observations to systematically quantify – for the first time – how often, for how long, to what extent, under what conditions and in what ways alien plants can impact plant community diversity. ALIENIMPACTS will develop mechanistic niche models, validated with empirical data from grasslands in North America, Europe and Australia, that will enable realistic scenarios of invasion biodiversity impacts to be forecast, now and in the future. Developing empirically accurate mechanistic models that predict invasions and their biodiversity impact is a highly ambitious goal. Its achievement will mark a step-change in ecological theory and understanding, will inform environmental policy and management, and address a critical research challenge of the Anthropocene: how to conserve the biodiversity of plants – the dominant life form on earth – under global environmental change.
Summary
The Anthropocene, the current geological epoch, is characterised by human-induced ecological changes, which have prompted a global biodiversity crisis. Human-introduced alien plants could help to offset native species loss, augmenting diversity and maintaining the services and capital that humans derive from nature. However, alien species that become invasive are themselves a key threat to biodiversity. Alien species thus presents a huge challenge for biodiversity conservation in the Anthropocene: should their arrival and establishment be inhibited or disregarded as they can potentially both exacerbate and ameliorate biodiversity loss? Coupling empirical and theoretical approaches, ALIENIMPACTS will directly address this challenge by developing an approach for accurately predicting impacts of alien plant invasions on plant community diversity and identifying the circumstances under which negative impacts will occur. Using temperate grasslands as a model system, ALIENIMPACTS will use innovative field experiments and global observations to systematically quantify – for the first time – how often, for how long, to what extent, under what conditions and in what ways alien plants can impact plant community diversity. ALIENIMPACTS will develop mechanistic niche models, validated with empirical data from grasslands in North America, Europe and Australia, that will enable realistic scenarios of invasion biodiversity impacts to be forecast, now and in the future. Developing empirically accurate mechanistic models that predict invasions and their biodiversity impact is a highly ambitious goal. Its achievement will mark a step-change in ecological theory and understanding, will inform environmental policy and management, and address a critical research challenge of the Anthropocene: how to conserve the biodiversity of plants – the dominant life form on earth – under global environmental change.
Max ERC Funding
1 999 997 €
Duration
Start date: 2021-04-01, End date: 2026-03-31
Project acronym ALLERGENE
Project Allergic multimorbidity from birth to young adulthood: determinants, epigenetic regulation and inflammatory processes
Researcher (PI) Marie Standl
Host Institution (HI) HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Country Germany
Call Details Starting Grant (StG), LS7, ERC-2020-STG
Summary The prevalence of allergic diseases, such as atopic eczema, asthma and rhinitis, has increased over the past decades and is currently estimated to be up to 40%. Prevention strategies play a pivotal role, as there are no curative treatments available. Therefore, the aim of ALLERGENE is to understand the complex interplay of genetic, environmental and lifestyle factors and to identify involved mechanisms that distinguish between young adults free of allergic diseases and those suffering from allergic multimorbidity. Therefore, the aims of the present project are to: 1. Define allergic disease trajectories from birth to young adulthood, describe their determinants and identify risk and protective early-life environmental and lifestyle factors contributing to progression towards allergic multimorbidity or remission of allergic diseases. 2. Investigate molecular mechanisms of epigenetic regulation of allergic disease trajectories and test effect modification by inclusion of selected environmental and lifestyle factors. 3. Characterise the underlying inflammation profile of allergic disease trajectories and determine interactions with environmental and lifestyle factors The project makes use of two long-standing, prospective German birth cohort studies, GINIplus and LISA, with available data from birth to young adulthood, and an extensive examination planned at age 25. Within this project, a comprehensive characterisation of allergic disease trajectories, their determinants, comorbidities, risk and protective factors across the life-course will be obtained. ALLERGENE will enhance the understanding of how modifiable factors contribute to allergic disease aetiology. This will be an essential prerequisite to develop effective early intervention strategies for susceptible populations and to identify disease-specific biomarkers for the development and progression of allergic diseases in the future.
Summary
The prevalence of allergic diseases, such as atopic eczema, asthma and rhinitis, has increased over the past decades and is currently estimated to be up to 40%. Prevention strategies play a pivotal role, as there are no curative treatments available. Therefore, the aim of ALLERGENE is to understand the complex interplay of genetic, environmental and lifestyle factors and to identify involved mechanisms that distinguish between young adults free of allergic diseases and those suffering from allergic multimorbidity. Therefore, the aims of the present project are to: 1. Define allergic disease trajectories from birth to young adulthood, describe their determinants and identify risk and protective early-life environmental and lifestyle factors contributing to progression towards allergic multimorbidity or remission of allergic diseases. 2. Investigate molecular mechanisms of epigenetic regulation of allergic disease trajectories and test effect modification by inclusion of selected environmental and lifestyle factors. 3. Characterise the underlying inflammation profile of allergic disease trajectories and determine interactions with environmental and lifestyle factors The project makes use of two long-standing, prospective German birth cohort studies, GINIplus and LISA, with available data from birth to young adulthood, and an extensive examination planned at age 25. Within this project, a comprehensive characterisation of allergic disease trajectories, their determinants, comorbidities, risk and protective factors across the life-course will be obtained. ALLERGENE will enhance the understanding of how modifiable factors contribute to allergic disease aetiology. This will be an essential prerequisite to develop effective early intervention strategies for susceptible populations and to identify disease-specific biomarkers for the development and progression of allergic diseases in the future.
Max ERC Funding
1 493 330 €
Duration
Start date: 2021-03-01, End date: 2026-02-28
Project acronym AllOptHIPP
Project All-Optical Dissection of Hippocampal Circuits Using Voltage Imaging
Researcher (PI) Yoav Adam
Host Institution (HI) THE HEBREW UNIVERSITY OF JERUSALEM
Country Israel
Call Details Starting Grant (StG), LS5, ERC-2020-STG
Summary The hippocampus is critical for the storage of episodic memories and has been extensively studied on its role in spatial memory. The hippocampus is also a central model for in vitro studies on the molecular, cellular and microcircuit basis for learning and memory. I propose to use a new technology that I developed to record and manipulate the membrane potential of multiple neurons, simultaneously, in behaving animals to reveal the mechanisms by which hippocampal circuits process spatial information. This research will bridge the gap between the in vitro mechanistic studies and the in vivo efforts to describe the spatial representations.
I first propose to employ the voltage imaging technology for detailed mechanistic studies of the function and plasticity of hippocampal microcircuits during place cell formation (Objective 1). To this end, we will combine voltage imaging with Optogenetics in head-fixed mice performing virtual navigation in familiar and novel environments. To expand to a ‘systems’ view on hippocampal plasticity, we will next establish a method for optical selection of single neurons based on their functional profile (Objective 2). We will use this technology to trace the long-range projections and the pre- and postsynaptic landscape of photo-selected CA1 neurons. In the last objective, we will combine both technologies to dissect the contribution of different entorhinal cell types (i.e. grid cells, border cells, and speed cells) to place cell formation in CA1 (objective 3). To this end, we will image the entorhinal cortex and photo-select cells based on their functional profiles. We will then image CA1 while manipulating the activity of the selected entorhinal cells. Our work will provide new discoveries on the mechanistic basis for spatial memory and will comprise a first step towards broader understanding of how the brain stores and retrieves episodic memories.
Summary
The hippocampus is critical for the storage of episodic memories and has been extensively studied on its role in spatial memory. The hippocampus is also a central model for in vitro studies on the molecular, cellular and microcircuit basis for learning and memory. I propose to use a new technology that I developed to record and manipulate the membrane potential of multiple neurons, simultaneously, in behaving animals to reveal the mechanisms by which hippocampal circuits process spatial information. This research will bridge the gap between the in vitro mechanistic studies and the in vivo efforts to describe the spatial representations.
I first propose to employ the voltage imaging technology for detailed mechanistic studies of the function and plasticity of hippocampal microcircuits during place cell formation (Objective 1). To this end, we will combine voltage imaging with Optogenetics in head-fixed mice performing virtual navigation in familiar and novel environments. To expand to a ‘systems’ view on hippocampal plasticity, we will next establish a method for optical selection of single neurons based on their functional profile (Objective 2). We will use this technology to trace the long-range projections and the pre- and postsynaptic landscape of photo-selected CA1 neurons. In the last objective, we will combine both technologies to dissect the contribution of different entorhinal cell types (i.e. grid cells, border cells, and speed cells) to place cell formation in CA1 (objective 3). To this end, we will image the entorhinal cortex and photo-select cells based on their functional profiles. We will then image CA1 while manipulating the activity of the selected entorhinal cells. Our work will provide new discoveries on the mechanistic basis for spatial memory and will comprise a first step towards broader understanding of how the brain stores and retrieves episodic memories.
Max ERC Funding
1 486 797 €
Duration
Start date: 2020-12-01, End date: 2025-11-30
Project acronym AngioUnrestUHD
Project Understanding and modulating vascular arrest with ultra-high definition
Researcher (PI) Rui Benedito
Host Institution (HI) CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Country Spain
Call Details Consolidator Grant (CoG), LS4, ERC-2020-COG
Summary Therapeutic modulation of vascular cell proliferation and migration is essential for the effective inhibition of angiogenesis in cancer or its induction in cardiovascular disease. The current view is that an increase in growth factor levels or mitogenic stimulation is beneficial for angiogenesis, since it leads to an increase in both endothelial proliferation and sprouting.
Through the use of innovative genetic and imaging approaches, we have recently elucidated a previously unappreciated, context-dependent mechanism whereby highly mitogenic environments can be detrimental for angiogenesis and lead to the cell-cycle arrest of endothelial cells (ECs), which ultimately impairs vascular growth.
The identified mechanism may explain the failed or inefficient promotion of functional angiogenesis by vascular growth factor delivery therapies, such as those used to treat ischemic cardiovascular disease. We propose that a better understanding and modulation of the identified hypermitogenic arrest process may allow angiogenesis to be induced more effectively.
Taking advantage of recent advances in DNA synthesis, CRISPR gene editing, microscopy and single-cell profiling technologies, we have developed new genetic tools, animal models and methods of broad relevance that enable the study of gene function with higher reliability, throughput and definition.
We propose to use these novel research tools and methods to significantly increase understanding of the biology of blood vessels in distinct physiological and pathological contexts.
We will then use this new knowledge to identify better strategies to promote vascular development in ischemic cardiovascular disease, heal vascular malformations, or inhibit angiogenesis in tumours.
Summary
Therapeutic modulation of vascular cell proliferation and migration is essential for the effective inhibition of angiogenesis in cancer or its induction in cardiovascular disease. The current view is that an increase in growth factor levels or mitogenic stimulation is beneficial for angiogenesis, since it leads to an increase in both endothelial proliferation and sprouting.
Through the use of innovative genetic and imaging approaches, we have recently elucidated a previously unappreciated, context-dependent mechanism whereby highly mitogenic environments can be detrimental for angiogenesis and lead to the cell-cycle arrest of endothelial cells (ECs), which ultimately impairs vascular growth.
The identified mechanism may explain the failed or inefficient promotion of functional angiogenesis by vascular growth factor delivery therapies, such as those used to treat ischemic cardiovascular disease. We propose that a better understanding and modulation of the identified hypermitogenic arrest process may allow angiogenesis to be induced more effectively.
Taking advantage of recent advances in DNA synthesis, CRISPR gene editing, microscopy and single-cell profiling technologies, we have developed new genetic tools, animal models and methods of broad relevance that enable the study of gene function with higher reliability, throughput and definition.
We propose to use these novel research tools and methods to significantly increase understanding of the biology of blood vessels in distinct physiological and pathological contexts.
We will then use this new knowledge to identify better strategies to promote vascular development in ischemic cardiovascular disease, heal vascular malformations, or inhibit angiogenesis in tumours.
Max ERC Funding
1 998 500 €
Duration
Start date: 2021-03-01, End date: 2026-02-28
Project acronym APHIDTRAP
Project Understanding and Preventing Plant Susceptibility to Aphids
Researcher (PI) Jorunn Bos
Host Institution (HI) UNIVERSITY OF DUNDEE
Country United Kingdom
Call Details Consolidator Grant (CoG), LS9, ERC-2020-COG
Summary Aphids are devastating insect pests of crops globally, and pose a major threat to food security. Crucially, there is a lack of durable genetic crop resistance against aphids, and current control relies almost exclusively on insecticides, which are costly and damaging to the environment and to which aphids develop resistance. These insects deliver proteins inside host plants, called effectors, to suppress the plant immune system and enhance susceptibility. I recently discovered that these effectors exhibit their activity via interacting with host plant proteins pointing to important conceptual parallels between plant-insect and plant-microbe interactions. This raises important new questions that urgently need to be addressed to enable development of novel protection strategies against aphids that are durable and sustainable. These are:
What is the mechanistic and structural basis of aphid effector-triggered susceptibility?
How can we interfere with aphid effector-triggered susceptibility?
APHIDTRAP will address these questions using an innovative strategy: 1) I will introduce a structural biology approach to the insect effector biology field to reveal protein 3D structures of aphid effectors and their host protein targets in bound and unbound state, and determine how mutations in these proteins affect interactions and protein functions. 2) I will use both natural variants and mutants of effectors and host protein targets, combined with in planta functional assays to explore plant-aphid molecular co-evolution. 3) I will identify host protein target interactomes and investigate how mutations affect network functionality. 4) I will use information generated in 1-3 to develop and apply a synthetic biology approach to prevent aphid effector-triggered susceptibility in potato crop plants.
APHIDTRAP’s vision is to elucidate the mechanisms that underlie susceptibility to aphids and investigate how we can interfere with these to reduce crop susceptibility to insect pests.
Summary
Aphids are devastating insect pests of crops globally, and pose a major threat to food security. Crucially, there is a lack of durable genetic crop resistance against aphids, and current control relies almost exclusively on insecticides, which are costly and damaging to the environment and to which aphids develop resistance. These insects deliver proteins inside host plants, called effectors, to suppress the plant immune system and enhance susceptibility. I recently discovered that these effectors exhibit their activity via interacting with host plant proteins pointing to important conceptual parallels between plant-insect and plant-microbe interactions. This raises important new questions that urgently need to be addressed to enable development of novel protection strategies against aphids that are durable and sustainable. These are:
What is the mechanistic and structural basis of aphid effector-triggered susceptibility?
How can we interfere with aphid effector-triggered susceptibility?
APHIDTRAP will address these questions using an innovative strategy: 1) I will introduce a structural biology approach to the insect effector biology field to reveal protein 3D structures of aphid effectors and their host protein targets in bound and unbound state, and determine how mutations in these proteins affect interactions and protein functions. 2) I will use both natural variants and mutants of effectors and host protein targets, combined with in planta functional assays to explore plant-aphid molecular co-evolution. 3) I will identify host protein target interactomes and investigate how mutations affect network functionality. 4) I will use information generated in 1-3 to develop and apply a synthetic biology approach to prevent aphid effector-triggered susceptibility in potato crop plants.
APHIDTRAP’s vision is to elucidate the mechanisms that underlie susceptibility to aphids and investigate how we can interfere with these to reduce crop susceptibility to insect pests.
Max ERC Funding
1 999 992 €
Duration
Start date: 2021-06-01, End date: 2026-05-31
Project acronym ASymbEL
Project A multilevel approach to address the role of Archaeal Symbionts in the Evolution of Life
Researcher (PI) Anja Spang
Host Institution (HI) STICHTING NEDERLANDSE WETENSCHAPPELIJK ONDERZOEK INSTITUTEN
Country Netherlands
Call Details Starting Grant (StG), LS8, ERC-2020-STG
Summary Microbial symbioses play an essential role in most aspects of life’s evolution and enabled major evolutionary events such as the origin of eukaryotes. But in spite of the importance of symbioses, our knowledge is based on a limited number of microbial host-symbiont systems, few of which include Archaea. Notably, recent cultivation-independent approaches have revealed two hugely diverse microbial groups of putative deep-branching archaeal and bacterial symbionts referred to as DPANN and CPR, respectively.
The major aims of ASymbEL are to test the hypotheses that (a) DPANN, together with CPR, have key positions in the tree of life, requiring to revise our view on the early evolution of cells and (b) that the diverse DPANN substantially shape the evolution of life through symbiont-host interactions. This will be achieved using a unique three-pronged strategy that will integrate knowledge from both micro- and macroevolutionary levels:
I will place the diverse DPANN in a rooted tree of life including CPR, reconcile the history of their genome content evolution and identify novel host-symbiont systems using sophisticated phylogenomic approaches combined with microscopy.
Further, I will elucidate fundamental principles of their genome evolution and interactions, for the first time using experimental evolution approaches to study two cultivated DPANN symbionts in co-culture with their hosts.
Finally, I will determine the dynamics of natural populations of known and newly identified archaeal host-symbiont systems and the influence of symbionts on host population structure and genome evolution using a unique approach combining single-cell, metagenomics and population genomics.
Altogether, this will allow to provide key insights into the global impact of these symbionts in the deep origins and diversification of cellular life on Earth. Thereby, ASymbEL paves the way for a deeper understanding of symbiotic evolutionary theory and the fundamental laws of cellular evolution.
Summary
Microbial symbioses play an essential role in most aspects of life’s evolution and enabled major evolutionary events such as the origin of eukaryotes. But in spite of the importance of symbioses, our knowledge is based on a limited number of microbial host-symbiont systems, few of which include Archaea. Notably, recent cultivation-independent approaches have revealed two hugely diverse microbial groups of putative deep-branching archaeal and bacterial symbionts referred to as DPANN and CPR, respectively.
The major aims of ASymbEL are to test the hypotheses that (a) DPANN, together with CPR, have key positions in the tree of life, requiring to revise our view on the early evolution of cells and (b) that the diverse DPANN substantially shape the evolution of life through symbiont-host interactions. This will be achieved using a unique three-pronged strategy that will integrate knowledge from both micro- and macroevolutionary levels:
I will place the diverse DPANN in a rooted tree of life including CPR, reconcile the history of their genome content evolution and identify novel host-symbiont systems using sophisticated phylogenomic approaches combined with microscopy.
Further, I will elucidate fundamental principles of their genome evolution and interactions, for the first time using experimental evolution approaches to study two cultivated DPANN symbionts in co-culture with their hosts.
Finally, I will determine the dynamics of natural populations of known and newly identified archaeal host-symbiont systems and the influence of symbionts on host population structure and genome evolution using a unique approach combining single-cell, metagenomics and population genomics.
Altogether, this will allow to provide key insights into the global impact of these symbionts in the deep origins and diversification of cellular life on Earth. Thereby, ASymbEL paves the way for a deeper understanding of symbiotic evolutionary theory and the fundamental laws of cellular evolution.
Max ERC Funding
1 869 946 €
Duration
Start date: 2021-02-01, End date: 2026-01-31